Very high-dose methotrexate (33.6 g/m2) as central nervous system preventive therapy for childhood acute lymphoblastic leukemia: results of National Cancer Institute/Children's Cancer Group trials CCG-191P, CCG-134P and CCG-144P
Authors:
- 1 January 2006
- journal article
- research article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 47 (12) , 2488-2504
Abstract
Between 1977 and 1991, the Children's Cancer Group and the National Cancer Institute conducted three trials of very high-dose methotrexate (33.6 g/m2; VHD-MTX) in place of cranial radiation (CRT) as central nervous system (CNS) preventive therapy, and assessed efficacy, acute toxicity and long-term neurocognitive outcome. CCG-191P compared VHD-MTX to CRT plus intrathecal methotrexate (IT-MTX) in 181 patients and demonstrated equivalent survival. However, patients treated with CRT had poorer performance on neurocognitive testing over time. CCG-134P evaluated the addition of intensified systemic and intrathecal therapy to VHD-MTX in 128 patients with high-risk acute lymphoblastic leukemia (ALL) and demonstrated reduced CNS relapse compared to the CCG-191P trial, but equivalent survival. CCG-144P compared VHD-MTX to IT-MTX alone in 175 patients with average-risk ALL and demonstrated equivalent survival. VHD-MTX was associated with significant toxicities, particularly neutropenia, transient hepatic dysfunction and sepsis. VHD-MTX achieved similar survival to other CNS-directed therapies without the long-term impact on intelligence, but with substantial acute toxicities.Keywords
This publication has 40 references indexed in Scilit:
- Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research HospitalBlood, 2004
- Methotrexate Infusions as Central Nervous System Prophylaxis in Children with Acute Lymphocytic Leukemia: The Norwegian ExperiencePediatric Hematology and Oncology, 2003
- Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01Blood, 2001
- Longitudinal Follow-Up of the Intellectual and Academic Functioning of Children Receiving Central Nervous System-Prophylactic Chemotherapy for LeukemiaJournal of Developmental & Behavioral Pediatrics, 1999
- Prevention of CNS recurrence in childhood ALL: Results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trialsKlinische Padiatrie, 1998
- Cognitive status of children treated with central nervous system prophylactic chemotherapy for acute lymphocytic leukemiaArchives of Clinical Neuropsychology, 1992
- Clinical Pharmacodynamics of High-Dose Methotrexate in Acute Lymphocytic LeukemiaNew England Journal of Medicine, 1986
- PRESYMPTOMATIC CENTRAL NERVOUS SYSTEM THERAPY IN PREVIOUSLY UNTREATED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA: COMPARISON OF 1800 RAD AND 2400 RADThe Lancet, 1981
- Treatment of leukemia with large doses of methotrexate and folinic acid: clinical-biochemical correlatesJournal of Clinical Investigation, 1969
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958